WorthPointe LLC Acquires New Position in HCA Healthcare, Inc. $HCA

WorthPointe LLC acquired a new stake in shares of HCA Healthcare, Inc. (NYSE:HCA) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 530 shares of the company’s stock, valued at approximately $203,000.

Several other large investors have also modified their holdings of the business. ORG Partners LLC raised its holdings in shares of HCA Healthcare by 27.9% in the 2nd quarter. ORG Partners LLC now owns 142 shares of the company’s stock valued at $55,000 after purchasing an additional 31 shares in the last quarter. Avantax Advisory Services Inc. raised its holdings in shares of HCA Healthcare by 0.4% in the 1st quarter. Avantax Advisory Services Inc. now owns 8,077 shares of the company’s stock valued at $2,791,000 after purchasing an additional 32 shares in the last quarter. Glenview Trust co raised its holdings in shares of HCA Healthcare by 2.3% in the 1st quarter. Glenview Trust co now owns 1,451 shares of the company’s stock valued at $501,000 after purchasing an additional 32 shares in the last quarter. Horizon Investments LLC raised its holdings in shares of HCA Healthcare by 1.1% in the 1st quarter. Horizon Investments LLC now owns 3,175 shares of the company’s stock valued at $1,097,000 after purchasing an additional 33 shares in the last quarter. Finally, Sivia Capital Partners LLC grew its position in shares of HCA Healthcare by 5.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 630 shares of the company’s stock worth $241,000 after buying an additional 33 shares during the last quarter. Institutional investors own 62.73% of the company’s stock.

HCA Healthcare Trading Up 0.3%

NYSE:HCA opened at $460.84 on Tuesday. The company’s 50 day moving average is $422.26 and its two-hundred day moving average is $388.13. The company has a market cap of $107.83 billion, a PE ratio of 17.81, a P/E/G ratio of 1.38 and a beta of 1.40. HCA Healthcare, Inc. has a twelve month low of $289.98 and a twelve month high of $478.19.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings data on Friday, October 24th. The company reported $6.96 EPS for the quarter, beating the consensus estimate of $5.64 by $1.32. The business had revenue of $19.16 billion for the quarter, compared to the consensus estimate of $18.55 billion. HCA Healthcare had a net margin of 8.53% and a negative return on equity of 792.25%. The business’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period in the prior year, the firm earned $4.90 EPS. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. As a group, analysts expect that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 29th. Stockholders of record on Monday, December 15th will be issued a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, December 15th. HCA Healthcare’s dividend payout ratio is 11.13%.

Insider Activity at HCA Healthcare

In other news, EVP Michael S. Cuffe sold 3,836 shares of the company’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $418.84, for a total value of $1,606,670.24. Following the sale, the executive vice president directly owned 31,503 shares of the company’s stock, valued at $13,194,716.52. This represents a 10.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on HCA. Zacks Research raised shares of HCA Healthcare from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 29th. Wolfe Research downgraded shares of HCA Healthcare from an “outperform” rating to a “peer perform” rating in a research report on Monday, July 28th. KeyCorp lifted their price objective on shares of HCA Healthcare from $465.00 to $475.00 and gave the stock an “overweight” rating in a research report on Monday, October 27th. Cowen reaffirmed a “buy” rating on shares of HCA Healthcare in a research report on Monday, October 27th. Finally, Robert W. Baird boosted their target price on shares of HCA Healthcare from $380.00 to $423.00 and gave the stock a “neutral” rating in a research report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, HCA Healthcare currently has a consensus rating of “Moderate Buy” and a consensus target price of $473.53.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.